Historical record - last NADAC effective date: 7/17/2024
Product Information
GABAPENTIN 300 MG CAPSULE is a generic product labeled by Cipla USA Inc., priced at $0.0358 per EA under NDC 69097094307. Its NADAC has been published 334 times since Mar 14, 2018.
FDA first approved this application on Dec 30, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Cipla USA Inc.NDC
69097094307
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
7/17/2024
Active Ingredients
GABAPENTINApproval Type
Generic (ANDA)
FDA Application
ANDA090705FDA Approved
12/30/2009
TE Code
AB
On Market Since
12/5/2017
Pharmacological Classes
Price Statistics
The NADAC for GABAPENTIN 300 MG CAPSULE has been published 334 times since Mar 14, 2018, and over the history we have for it it has declined 17.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0358 per EA |
|---|---|
| All-time high | $0.0601 (Jan 16, 2019) |
| All-time low | $0.0358 (Jul 17, 2024) |
| Median price | $0.0483 |
| Average price | $0.0486 |
| Largest weekly change | -13.8% (Jan 23, 2019) |
| Weeks tracked | 334 |
| Tracking since | Mar 14, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-13.0%
5Y
-27.9%
All
-17.9%
Last surveyed Jul 31, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 16% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of GABAPENTIN 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN 300 MG CAPSULE, manufactured by Cipla USA Inc., is $0.0358 per EA (NDC 69097094307), effective Jul 31, 2024.
How has the price of GABAPENTIN 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for GABAPENTIN 300 MG CAPSULE has declined 17.9%. It has been tracked across 334 weekly CMS publications since Mar 14, 2018.
What are the highest and lowest recorded NADAC prices for GABAPENTIN 300 MG CAPSULE?
Since Mar 14, 2018, the NADAC for GABAPENTIN 300 MG CAPSULE has ranged from a low of $0.0358 (Jul 17, 2024) to a high of $0.0601 (Jan 16, 2019), with a median of $0.0483 per EA.
Are there cheaper alternatives to GABAPENTIN 300 MG CAPSULE?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GABAPENTIN 300 MG CAPSULE, is $0.0301 per EA — about 16% below GABAPENTIN 300 MG CAPSULE.
Who manufactures GABAPENTIN 300 MG CAPSULE?
GABAPENTIN 300 MG CAPSULE (NDC 69097094307) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.